Early changes in immunoglobulin G levels during immune checkpoint inhibitor treatment are associated with survival in hepatocellular carcinoma patients.
Lorenz BalcarDavid Josef Maria BauerKatharina PomejTobias MeischlMattias MandorferThomas ReibergerMichael TraunerBernhard ScheinerMatthias PinterPublished in: PloS one (2023)
Our study proposes a higher increase of Δ-IgG upon ICI treatment as a negative prognostic marker in patients with HCC, independent of underlying liver disease severity. These results require independent validation.